The DOI matches its Crossref record; 54 of the 56 references it cites were found in a registry or an index.
Response of latent syphilis or neurosyphilis to ceftriaxone therapy in persons infected with human immunodeficiency virus.
Abstract
Objective To evaluate the effect of ceftriaxone in treating latent syphilis or asymptomatic neurosyphilis in patients infected with the human immunodeficiency virus (HIV).Design Follow-up study of patients treated at two HIV-based clinics during 16 months from 1989 to 1991.Patients Patients were those in whom a clinical diagnosis of latent syphilis or asymptomatic neurosyphilis was made, who received all recommended doses of antimicrobial therapy, and who returned for follow-up visits for 6 or more months.Results Forty-three patients were treated with ceftriaxone, 1 to 2 g daily for 10 to 14 days. Thirteen underwent lumbar puncture before treatment; 7 (58%) had documented neurosyphilis (pleocytosis in 5, elevated protein levels in 6, VDRL reactive in cerebrospinal fluid [CSF] in 7), and 6 had documented latent syphilis (entirely normal CSF). The remaining 30 were said to have presumed latent syphilis. There was no relation between the diagnosis and the selected dosage of ceftriaxone. Response rates were similar in those who had documented neurosyphilis and documented or presumed latent syphilis. Overall, 28 patients (65%) responded to therapy, 5 (12%) were serofast, 9 (21%) had a serologic relapse, and 1 (2%) who experienced progression to symptomatic neurosyphilis was a therapeutic failure. Thirteen patients received benzathine penicillin for presumed latent syphilis; results were similar to those observed after ceftriaxone therapy, with 8 (62%) responders, 1 (8%) serofast, 2 (15%) relapses, and 2 (15%) failures. CD4 cell counts in responders were not different from those who failed to respond.Conclusions Even in the absence of neurologic symptoms, half of the HIV-infected persons who have serologic evidence of syphilis may have neurosyphilis. Although ceftriaxone achieves high serum and CSF levels, 10 to 14 days of treatment with this drug were associated with a 23% failure rate in HIV-infected patients who had latent syphilis or asymptomatic neurosyphilis. Three doses of benzathine penicillin did not have a significantly higher relapse rate and may provide appropriate therapy, at least for documented latent syphilis in persons co-infected with HIV. Studies comparing ceftriaxone with 10 to 14 doses of procaine penicillin are needed to determine the most cost-effective treatment for asymptomatic neurosyphilis or presumed latent syphilis in this group of patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Small observational studies conducted among persons with HIV and neurosyphilis report that ceftriaxone 1–2 g IV daily for 10–14 days might be effective as an alternative agent (628–630).”
From Sexually Transmitted Infections Treatment Guidelines, 2021 (2021) · cites this paper as [629]
In the citing paper
“Several different ceftriaxone regimens have been shown to be effective for the treatment of early syphilis.104–113”
From BASHH UK guidelines for the management of syphilis 2024 (2024) · cites this paper as [110]
Citations
Cites
Principles and Practice of Infectious Diseases.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-818_5 · Cited by 12,045
Lukehart, S. A., Hook, E. W., Baker-Zander, S. A., Collier, A. C., Critchlow, C. W., & Handsfield, H. H. (1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-109-11-855 · Cited by 603
Johns, D. R., Tierney, M. R., & Felsenstein, D. (1987) · New England Journal of Medicine · doi:10.1056/nejm198706183162503 · Cited by 556
The Association Between Genital Ulcer Disease and Acquisition of HIV Infection in Homosexual Men
Stamm, W. E. (1988) · JAMA · doi:10.1001/jama.1988.03410100119036 · Cited by 438
Quinn, T. C., Classer, D., Cannon, R. O., Matuszak, D. L., DUNNING, R. W., Kline, R. L., Campbell, C. H., Israel, E., Fauci, A. S., & Hook, E. W. (1988) · New England Journal of Medicine · doi:10.1056/nejm198801283180401 · Cited by 358
Musher, D. M., Hamill, R. J., & Baughn, R. E. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-113-11-872 · Cited by 352
Berry, C., Hooton, T. M., Collier, A. C., & Lukehart, S. A. (1987) · New England Journal of Medicine · doi:10.1056/nejm198706183162507 · Cited by 340
Primary and Secondary Syphilis in the United States
Axnick, N. W., & Brown, W. J. (1961) · Public Health Reports (1896-1970) · doi:10.2307/4591347 · Cited by 288
Hicks, C. B., BENSON, P. M., LUPTON, G. P., & TRAMONT, E. C. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-4-492 · Cited by 269
Serologic Response to Treatment of Infectious Syphilis
Romanowski, B., Sutherland, R. L., Fick, G. H., Mooney, D., & Love, E. J. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-12-1005 · Cited by 263
Cited by
Sorted by citations
Sexually Transmitted Infections Treatment Guidelines, 2021
Workowski, K. A., Bachmann, L. H., Chan, P. A., Johnston, C. M., Muzny, C. A., Park, I., Reno, H., Zenilman, J. M., & Bolan, G. A. (2021) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr7004a1 · Cited by 3,018
Sexually Transmitted Diseases Treatment Guidelines, 2010
Workowski, K., & BOLAN, G. A. (2011) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2011.04.006 · Cited by 2,074
Rolfs, R. T., Joesoef, M. R., Hendershot, E. F., Rompalo, A. M., Augenbraun, M. H., Chiu, M., Bolan, G., Johnson, S. C., French, P., Steen, E., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707313370504 · Cited by 550
Syphilis: Review with Emphasis on Clinical, Epidemiologic, and Some Biologic Features
Singh, A. E., & Romanowski, B. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.2.187 · Cited by 638
“reported success rates of 77% when patients with latent syphilis or neurosyphilis were treated with ceftriaxone, 1 to 2 g/day (77).”
Background2020 European guideline on the management of syphilis
Janier, M., Unemo, M., Dupin, N., Tiplica, G. S., Potočnik, M., & Patel, R. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16946 · Cited by 421
Metadata
- Authors
- Dowell, M. E., Ross, P. G., Musher, D. M., Cate, T. R., & Baughn, R. E.
- Affiliations
- United States Department of Veterans Affairs (US)
- Harris Health System (US)
- Baylor College of Medicine (US)
- Corresponding author
- Musher, Daniel M.
- ORCID
- Musher, Daniel M.
- Venue
- The American Journal of Medicine
- Publisher
- Elsevier BV
- Published
- 1992-11
- Volume
- 93
- Issue
- 5
- Pages
- 481-488
- ISSN
- 0002-9343 (ISSN-L)
- OpenAlex
- W2105769864
- Cited by
- 133
- References
- 56
- Citations by year
- 2025: 2 · 2024: 4 · 2023: 1 · 2022: 4 · 2021: 7 · 2020: 3 · 2018: 2 · 2017: 4 · 2016: 1 · 2015: 10 · 2014: 8 · 2013: 3 · 2012: 1
- FWCI
- 3.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The American Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Syphilis Diagnosis and Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Historical Medical Research and Treatments
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Keywords
- ceftriaxone, latent syphilis, neurosyphilis, HIV infection, benzathine penicillin, treatment response, CD4 count, cerebrospinal fluid, syphilis screening, treatment failure, HIV-associated neurosyphilis, VDRL serology, lumbar puncture, treatment duration, benzathine
- MeSH terms
- Adult, Ceftriaxone, Female, Humans, Male, Neurosyphilis, Penicillin G Benzathine, Syphilis Serodiagnosis, Syphilis, Latent, HIV Infections, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review